Aberdeen Group’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $44.2M | Buy |
551,553
+48,051
| +10% | +$3.96M | 0.07% | 235 |
|
|
2025
Q4 | $42.9M | Sell |
503,502
-5,130
| -1% | -$421K | 0.07% | 245 |
|
|
2025
Q3 | $39.3M | Sell |
508,632
-13,543
| -3% | -$1.06M | 0.06% | 251 |
|
|
2025
Q2 | $40.8M | Buy |
522,175
+47,872
| +10% | +$3.57M | 0.07% | 240 |
|
|
2025
Q1 | $34.1M | Sell |
474,303
-614,049
| -56% | -$44M | 0.07% | 255 |
|
|
2024
Q4 | $80.5M | Sell |
1,088,352
-223,492
| -17% | -$15.6M | 0.15% | 146 |
|
|
2024
Q3 | $85.8M | Buy |
1,311,844
+22,271
| +2% | +$1.62M | 0.16% | 150 |
|
|
2024
Q2 | $119M | Buy |
1,289,573
+32,513
| +3% | +$2.88M | 0.23% | 98 |
|
|
2024
Q1 | $120M | Sell |
1,257,060
-48,794
| -4% | -$4.1M | 0.24% | 101 |
|
|
2023
Q4 | $99.6M | Buy |
1,305,854
+738,648
| +130% | +$51.4M | 0.22% | 110 |
|
|
2023
Q3 | $39.3M | Buy |
567,206
+24,525
| +5% | +$1.97M | 0.1% | 193 |
|
|
2023
Q2 | $51.2M | Buy |
542,681
+45,147
| +9% | +$3.92M | 0.12% | 166 |
|
|
2023
Q1 | $41.2M | Buy |
497,534
+41,010
| +9% | +$3.22M | 0.1% | 202 |
|
|
2022
Q4 | $34.1M | Buy |
456,524
+32,341
| +8% | +$2.49M | 0.09% | 240 |
|
|
2022
Q3 | $35M | Buy |
424,183
+170,556
| +67% | +$16.4M | 0.1% | 219 |
|
|
2022
Q2 | $24.2M | Buy |
253,627
+22,731
| +10% | +$2.35M | 0.08% | 255 |
|
|
2022
Q1 | $27.7M | Sell |
230,896
-7,720
| -3% | -$866K | 0.07% | 259 |
|
|
2021
Q4 | $30.9M | Sell |
238,616
-12,715
| -5% | -$1.48M | 0.07% | 268 |
|
|
2021
Q3 | $28.7M | Buy |
251,331
+21,359
| +9% | +$2.44M | 0.06% | 282 |
|
|
2021
Q2 | $23.8M | Sell |
229,972
-4,263
| -2% | -$402K | 0.05% | 321 |
|
|
2021
Q1 | $19.6M | Buy |
234,235
+9,644
| +4% | +$815K | 0.04% | 348 |
|
|
2020
Q4 | $20.5M | Buy |
224,591
+6,479
| +3% | +$537K | 0.05% | 317 |
|
|
2020
Q3 | $17.4M | Sell |
218,112
-32,974
| -13% | -$2.57M | 0.05% | 319 |
|
|
2020
Q2 | $17.4M | Sell |
251,086
-8,735
| -3% | -$621K | 0.05% | 320 |
|
|
2020
Q1 | $16.4M | Buy |
259,821
+4,995
| +2% | +$360K | 0.05% | 305 |
|
|
2019
Q4 | $19.8M | Buy |
254,826
+10,713
| +4% | +$837K | 0.05% | 332 |
|
|
2019
Q3 | $17.9M | Sell |
244,113
-2,322
| -0.9% | -$163K | 0.04% | 345 |
|
|
2019
Q2 | $15.2M | Sell |
246,435
-7,356
| -3% | -$445K | 0.03% | 417 |
|
|
2019
Q1 | $16.2M | Buy |
253,791
+89,625
| +55% | +$5.11M | 0.04% | 400 |
|
|
2018
Q4 | $8.21M | Sell |
164,166
-80,211
| -33% | -$4.06M | 0.02% | 479 |
|
|
2018
Q3 | $14.2M | Buy |
244,377
+19,587
| +9% | +$958K | 0.03% | 441 |
|
|
2018
Q2 | $10.9M | Buy |
224,790
+35,685
| +19% | +$1.67M | 0.02% | 463 |
|
|
2018
Q1 | $8.79M | Sell |
189,105
-2,061
| -1% | -$89.5K | 0.02% | 466 |
|
|
2017
Q4 | $7.18M | Buy |
191,166
+3,150
| +2% | +$116K | 0.01% | 507 |
|
|
2017
Q3 | $6.85M | Buy |
+188,016
| New | +$7.17M | 0.01% | 514 |
|
Other funds holding EW
VCM
VPM
Aberdeen Group's EW Position: Q1 2026 in Review
Aberdeen Group increased its Edwards Lifesciences (EW) stake by 9.5% in Q1 2026, buying an estimated $3.96M and bringing the position to 551,553 shares worth $44.2M. The position accounts for 0.07% of the portfolio, ranked #235.
Aberdeen Group first reported a position in EW in Q3 2017 and has held it in 35 quarters since. The position peaked at $120M in Q1 2024. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Aberdeen Group held 551,553 shares of Edwards Lifesciences worth $44.2M as of Q1 2026.
- Aberdeen Group bought 48,051 Edwards Lifesciences shares in Q1 2026, an estimated $3.96M.
- Edwards Lifesciences made up 0.07% of Aberdeen Group's portfolio in Q1 2026, its #235 holding.
- Aberdeen Group first reported a position in Edwards Lifesciences in Q3 2017 and has held it in 35 quarters since.
- Aberdeen Group's Edwards Lifesciences position peaked at $120M in Q1 2024.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Aberdeen Group's 13F filing for Q1 2026, filed 29 Apr 2026.